AK 0529

Drug Profile

AK 0529

Alternative Names: AK-0529

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Ark Biosciences
  • Class Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 28 Jun 2016 Ark Biosciences terminates phase I trial in Respiratory syncytial virus infections (In infants) in Australia (NCT02460016)
  • 30 Jan 2016 Ark Biosciences plans to initiate the phase II VICTOR trial for Respiratory syncytial virus infections (In infants) in Australia (PO) (NCT02654171)
  • 04 Jun 2015 Ark Biosciences plans a phase Ib trial in Respiratory syncytial virus infections (In infants) in Australia (NCT02460016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top